Abstract:OBJECTIVE:To screen out the specific antibody clones against amyloid beta peptide 40, and clone the antibody gene and express it in a bacterial system, so as to provide a solid basis for novel diagnostic and therapeutic methods for Alzheimer's Disease.METHODS:beta amyloid peptide 40 was bound on the solid surface of Nunc plates as antigen to screen the binding clones from a phage-display human single-chain Fv antibody library. After five rounds of bio-panning, the host E. coli TG1 was infected with eluted filamentous phage from the last turn of selection. 55 well-separated colonies were picked randomly from the plates and the specific positive clones were identified by ELISA test. The single-chain Fv antibody gene was sequenced and their amino acids sequence was deduced. The scFv antibody gene was sub-cloned into a protokayotic expression vector pGEX-6P-1 and transformed into bacteria strain BL21 to express the glutathione-S-transferase (GST) fusion single-chain antibody.RESULTS:ELISA test showed that 33 of the 55 clones could bind amyloid beta peptide 40 and 10 of the 33 clones could be inhibited by amyloid beta peptide 40 itself to below 50% of its original binding activities. Five of the 10 clones could also be inhibited by amyloid beta peptide 1-16 to the same level, which meant that the binding epitope of the antibody from the 5 clones was between first to sixteenth amino acids at amino-end of amyloid beta peptide 40. DNA sequencing data demonstrated that the gene of the single-chain antibody specifically against amyloid beta peptide 40 was consisted of 768 bp and the deduced amino acids sequence confirmed its typical antibody structure. The complement determinant regions and framework regions were discriminated empirically. After cloning the antibody gene into a protokayotic system, the GST fusion antibody was expressed as the expected size.CONCLUSIONS:After five rounds of bio-panning and subsequently serial ELISA testing, the specific antibody clones against amyloid beta peptide 40 were screened out successfully. The antibody gene DNA sequence and amino acids sequence were analyzed and confirmed. The fusion antibody was expressed as expected in the bacterial system.

Expression of BRI–amyloid Β Peptide Fusion Proteins: a Novel Method for Specific High-Level Expression of Amyloid Β Peptides

Expression of PrP(C) As HIS-fusion Form in a Baculovirus System and Conversion of Expressed PrP-sen to PrP-res in a Cell-Free System.

An Enzyme-Linked Immunosorbent Assay To Compare The Affinity Of Chemical Compounds For Beta-Amyloid Peptide As A Monomer

High Level Expression Purification and Character Research of Human Fusion Antibody for Anti-Aβ in the Yeast Pichia Pastoris

[Construction and Expression of Recombinant Adenovirus Expression Vector of Beta-Defensin-2].

Identification and characterization of C-terminal fragments of the beta-amyloid precursor produced in cell culture.

Effects of a 15-Amino-acid Isoform of Amyloid- Β Expressed by Silkworm Pupae on B6C3-Tg Alzheimer’s Disease Transgenic Mice

Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

Therapeutic effects of a novel synthetic α-secretase

Gene therapy using Aβ variants for amyloid reduction

Liquid-Liquid Phase Separation Protects Amyloidogenic and Aggregation-Prone Peptides in Heterologous Expression Systems

Distinctive Roles Of Different Beta-Amyloid 42 Aggregates In Modulation Of Synaptic Functions

In vivo liquid–liquid phase separation protects amyloidogenic and aggregation‐prone peptides during overexpression in Escherichia coli

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Phage display affords peptides that modulate beta-amyloid aggregation.

A novel mouse model for N-terminal truncated Aβ2-x generation through meprin β overexpression in astrocytes

Aβ-targeting synNotch Receptor for Alzheimer′s Disease: Expanding Applications to Extracellular Protein Aggregates

Γ-Secretase, Evidence for Multiple Proteolytic Activities and Influence of Membrane Positioning of Substrate on Generation of Amyloid Β Peptides of Varying Length

Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain

[Cloning and Expression of Human Single-Chain Fv Antibody Against Amyloid Beta Peptide Involved in Alzheimer's Disease].

Turn-on chemiluminescence probes and dual-amplification of signal for detection of amyloid beta species in vivo